There’s a new marketing agreement between Icon, a contract research organization, and PHT, a provider of electronic patient diaries. Icon will provide PHT’s LogPad electronic patient reported outcomes solution. PHT clients will have access to Icon’s life cycle science group’s significant experience in both the design and implementation of patient-reported outcomes (PRO) research and it ICOPhone offering, which use interactive voice response (IVR) and interactive web response (IWR) technology. “Icon has partnered with PHT in order to seamlessly offer clients a hand-held electronic diary or mobile-site-based tablet solution,” said Kris Gustafson, senior VP of interactive technologies and life cycle sciences at Icon.

Advanced Clinical Software (ACS), a developer of clinical trial management software, announced the release of StudyManager 13.5, an upgrade to its end-to-end solution for research sites, universities, and hospitals. The new software streamlines research, providing real-time access to key enrollment and financial metrics. In addition to enhanced scheduling features, 13.5 offers integration with Allscripts’ Touchworks EHR. “By integrating with Allscripts and adding strong new scheduling features to an already deep product,” said Bruce Schatzman, founder and CEO of ACS, “StudyManager 13.5 provides site managers and researchers with tools that ensure clinical research is conducted accurately and efficiently.”

RadPharm, an imaging contract research organization (CRO), announced that CEO Ronald Berg is a finalist for The New Jersey Ernst & Young entrepreneur of the year 2008 awards. “To be selected a finalist is an honor that is directly attributable to RadPharm as a company, as much as it is an honor to me personally,” said Berg. The award winners will be announced at a special gala event on Thursday, June 19, 2008, at the Marriott Teaneck at Glenpointe, Teaneck, New Jersey.

The Ewing Marion Kauffman Foundation says Merck, Eli Lilly and Johnson & Johnson are now counting on China and India for advanced research and development, not just access to patients. Indian and Chinese scientists are developing the ability to innovate and create their own intellectual property, a new report from the foundation suggests.

invivodata, a provider of electronic patient reported outcome (ePRO) technology, will demonstrate product enhancements and new ePRO solutions at the Drug Information Association (DIA) annual meeting in Boston, June 22–26. Scientists from invivodata’s PRO consulting division will be featured speakers at the event. In booth 600, invivodata representatives will showcase its second-generation, large-screen, site-based ePRO solution—the SitePRO tablet. We wrote about that device here.

Arizona’s nonprofit Critical Path Institute announced a milestone in its effort to advance the FDA’s Critical Path agenda. Seven new renal tests have been deemed by the agencies as “qualified” markers of drug-induced kidney injury in animal studies. More than 200 scientists from industry, FDA and EMEA appear to have agreed on the merits of the tests via the Predictive Safety Testing Consortium. Raymond Woosley, president and CEO of the Critical Path Institute, stated: “the PSTC is proving that government and industry scientists can and should work together to improve the methods for testing the safety of new drugs. The qualification of these seven new tests is the critical first step towards their use in clinical drug development.” Wm. Mattes, the institute’s director of the PSTC, said: “Using current kidney tests that were developed over 100 years ago, 70 percent of kidney function must be lost before damage can be detected. The newly approved biomarkers are far more sensitive and specific for drug-induced kidney damage.” The PSTC is now trying to assess the renal tests for use in human projects.

Have a news release? Send it to .(JavaScript must be enabled to view this email address).

d9A2t49mkex